Through our ML approach, we found that measures of AD neuropathology (CSF amyloid and tau and cerebral amyloid assessed by PET) and neuronal injury (assessed by FDG-PET and structural MRI) explained the most variance in separating fast versus slow progression from MCI to AD dementia. This evidence concerns the gene MAPT and Alzheimer disease.